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ABSTRACT
Although gemcitabine is the most commonly used drug for treating
pancreatic cancers, acquired gemcitabine resistance in a sub-
stantial number of patients appears to hinder its effectiveness
in successful treatment of this dreadful disease. To understand
acquired gemcitabine resistance, we generated a gemcitabine-
resistant pancreatic cancer cell line using stepwise selection and
found that, in addition to the known mechanisms of upregulated
expression of ribonucleotide reductase, 14-3-3s expression is
dramatically upregulated, and that 14-3-3s overexpression
contributes to the acquired resistance to gemcitabine and
cross-resistance to cytarabine. We also found that the increased
14-3-3s expression in the gemcitabine-resistant cells is due to
demethylation of the 14-3-3s gene during gemcitabine selection,
which could be partially reversed with removal of the gemcitabine
selection pressure. Most importantly, the reversible methylation/
demethylation of the 14-3-3s gene appears to be carried out by
DNAmethyltransferase 1 under regulation by Uhrf1. These findings
suggest that the epigenetic regulation of gene expression may play
an important role in gemcitabine resistance, and that epigenetic
modification is reversible in response to gemcitabine treatment.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) ranks as the
fourth most common cause of human death by cancer in the
Western world, with a 5-year survival rate of less than 5%
and a median survival of 6 months after diagnosis, thereby
exhibiting the poorest prognosis of all solid tumors. Although
gemcitabine, a deoxycitidine analog, is currently the standard
and most commonly used drug for treating PDAC, almost all
PDAC patients eventually develop resistance to gemcitabine,
the main cause of relapse and death.
Altered expression of enzymes involved in gemcitabine
uptake and metabolism such as hENT1 and ribonucleotide
reductase (RRM1 and RRM2) has been shown to contrib-
ute to both intrinsic and acquired gemcitabine resistance
(Voutsadakis, 2011). Recently, overexpression of 14-3-3s in
PDAC has also been observed andwas thought to contribute to
intrinsic resistance and poor prognosis (Hustinx et al., 2005;
Neupane and Korc, 2008; Li et al., 2010). 14-3-3s belongs to
the human 14-3-3 protein family of seven members (b, «, u/t, z,
s, g, h), which are phosphoserine/phosphothreonine-binding
proteins and play important roles inmultiple biologic processes
(Li et al., 2009). Of these seven 14-3-3 proteins, the s isoform
is particularly intriguing due to its association with poor
prognosis, and because its expression is frequently lost in
some cancers but increased in other cancers (Li et al., 2009).
Uhrf1 (ubiquitin-like, containing PHD and ring finger
domains 1) is a multidomain protein important in epigenetic
regulation. Mammalian Uhrf1 also contains a SRA (SET and
RING associated) domain, which is responsible for binding to
histones and methyl-CpG dinucleotides with a preference for
hemimethylated CpG sites. Uhrf1 binds to hemimethylated
CpG sites and recruits DNA methyltransferase 1 (DNMT1) to
methylate the newly synthesized strands, and thus it plays an
important role in facilitating and maintaining DNA methyl-
ation (Bostick et al., 2007; Sharif et al., 2007).
In this study, we found that 14-3-3s expression is dramat-
ically upregulated in a gemcitabine-selected derivative clone of
PDAC cell line,MiaPaCa-2, and the overexpression contributes
to the acquired resistance to gemcitabine and cross-resistance
to cytarabine (Ara-C). We also found that the increased 14-3-3s
expression is due to demethylation of the 14-3-3s gene during
gemcitabine selection, which could be partially reversed with
removal of gemcitabine selection. The reversible methylation/
demethylation of the 14-3-3s gene is carried out by DNMT1
under Uhrf1 regulation. Together, we conclude that 14-3-3s
expression can be upregulated in PDAC in response to
gemcitabine treatment by reversible gene demethylation, and
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that the increased 14-3-3s expression contributes to acquired
gemcitabine resistance in PDAC.
Materials and Methods
Metafectene Pro transfection reagent was obtained from Biontex
(München, Germany). Small interfering RNAs (siRNAs) targeting
14-3-3s, Uhrf1, DNMT1, DNMT3a, as well as DNMT3b and anti-
bodies against 14-3-3u, 14-3-3z, DNMT1, and DNMT3a were pur-
chased from Santa Cruz Biotechnology (Dallas, TX). DNMT1 antibody
for chromatin immunoprecipitation (ChIP) assay was from Abcam
(Cambridge, UK). Antibodies against 14-3-3s and RRM1, the ChIP
Assay kit, and the CpGenome Universal DNA Modification kit were
purchased from EMD Millipore (Billerica, MA). Antibodies against
Uhrf1 and FASN were from BD Biosciences (San Jose, CA). Anti-
bodies against hENT1, histone H3, and RRM2 were from Epitomics
(Burlingame, CA), Cell Signaling Technology (Danvers, MA), and
generated in house (Dong et al., 2005), respectively. Lipofectamine,
pcDNA3.1(1) plasmid, and G418 were from Invitrogen (Carlsbad,
CA). RNeasy Mini kit and Qiagen Blood and Cell Culture DNA Kit
were fromQiagen (Germantown,MD). The iScript cDNA synthesis kit
and the SYBR Green polymerase chain reaction (PCR) master mix
were from Bio-Rad (Hercules, CA) and Applied Biosystems (Grand
Island, NY), respectively. Gemcitabine was purchased from Besse
Medical (West Chester, OH), whereas Ara-C, 5-fluorouracil (5-FU),
Adriamycin (doxorubicin), mitoxantrone, and nocodazole were from
Sigma-Aldrich (St. Louis, MO). All other chemicals were purchased
from Sigma-Aldrich or Fisher Scientific (Waltham, MA).
Cell Lines, Cultures, and Transfections. Human pancreatic
cancer cell line MiaPaCa-2 (American Type Culture Collection,
Manassas, VA) and its derivative lines G3K and G3K/REV were
cultured at 37°C, 5% CO2 in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum and 2.5% horse serum.
G3K cells were generated by stepwise selection of MiaPaCa-2 with
gradually increasing concentrations of gemcitabine starting at
4 nM. G3K cells were clonal and maintained in the presence of 3 mM
gemcitabine. The G3K/REV cell line was generated by culturing the
drug-resistant G3K cells in the absence of gemcitabine for 6 months,
and it partially lost its gemcitabine resistance phenotype. MCF7 and
its derivative lines MCF7/AdVp3000 and MCF7/AdVp3000/Rev were
gifts from Dr. Susan E. Bates (National Cancer Institute, Bethesda,
MD), and were cultured as previously described (Liu et al., 2006). The
cell lines were authenticated by analysis of tandem repeat sequences
on September 17, 2013.
For transient knockdown of target genes, cells were plated in a six-
well plate at a density of 1.5–3 105 cells/well and cultured overnight
in complete medium. About 60–120 pmol siRNAs of target genes or
control scrambled siRNAs were diluted in serum-free Opti-MEM
medium (Invitrogen) and then transiently transfected into cells using
Metafectene Pro transfection reagent as previously described (Liu
et al., 2008). For stable knockdown, pSilencer-s containing 14-3-3s
short hairpin RNA (shRNA) engineered in a previous study (Han
et al., 2006) was transfected into G3K cells using Lipofectamine,
and stable clones were selected using 1 mg/ml G418 as previously
described (Han et al., 2006). The stable clones were maintained in
complete medium supplemented with 200 mg/ml G418. For stable
transfection, the cDNA of 14-3-3s was engineered into pcDNA3.1(1)
and transfected into MiaPaCa-2 cells using Lipofectamine. Stable
clones were selected using 1mg/ml G418 as previously described (Han
et al., 2006; Liu et al., 2006). The stable clones were maintained in
complete medium supplemented with 200 mg/ml G418.
Cell Lysate Preparation and Western Blot Analysis. Cul-
tured cells were harvested, washed with phosphate-buffered saline,
and lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
0.5% Nonidet P-40, 50 mMNaF, 1 mM sodium orthovanadate, 1 mM
dithiothreitol, 0.1% SDS, and 2 mM phenyl-methylsulfonyl fluoride)
for 30 minutes at 4°C with constant agitation. The cell lysates were
then sonicated briefly followed by centrifugation (16,000g at 4°C) for
15 minutes to remove insoluble materials. The protein concentrations
of supernatants were measured by Bradford assay.
Cell lysates were separated by SDS-PAGE and transferred to
a polyvinylidene fluoride membrane followed by a 2-hour incubation
in blocking solution (phosphate-buffered saline containing 5% nonfat
dried milk and 0.1% Tween 20) and a 2-hour incubation with primary
antibodies. After extensive washing, immunoreactivity was detected
with specific secondary antibodies conjugated to horseradish perox-
idase. Signals were captured using enhanced chemiluminescence and
X-ray film.
Survival Assay. Survival assay was performed as previously
described using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] colorimetric assay (Yang et al., 2002, 2007). In brief, cells
were seeded in a 96-well plate at 2000–3000 cells/well and cultured
for 24 hours followed by treatment with a different dose of anticancer
drugs and incubated continuously for 3 days followed by addition of
MTT (5 mg/ml) to a final concentration of 0.5 mg/ml and incubation
of the plates at 37°C for 4 hours. The absorbance at 570 nmwasmeasured
using an automated plate reader and analyzed using GraphPad Prism
software (GraphPad Software, La Jolla, CA) to generate fitted curve
and IC50. Relative resistance factor (RRF) is calculated using the
following formula: RRF 5 IC50(test)/IC50(control).
Quantitative Reverse-Transcription PCR. Quantitative reverse-
transcription PCR (RT-PCR) was performed as described pre-
viously (Liu et al., 2007; Dong et al., 2009). In brief, total RNA was
extracted using the RNeasy Mini Kit followed by reverse tran-
scription using the iScript cDNA synthesis kit and quantitative
PCR using the SYBR Green PCR master mix. The primer pairs used
are as follows: 59- TAGGCGCTGTTCTTGCTCCAA-39 (forward) and
59- ACCAGTGGTTAGGTGCGCTCA-39 (reverse) for 14-3-3s; 59- GGCAAGT-
TCTCCGAGGTCTCTG-39 (forward) and 59- TGGTACATGGCTTTTCGA-
TAGGA-39 (reverse) for DNMT3b, 59-TCTGGCTTTCTTTGCAGCAA-39
(forward) and 59-CAGCGGGCTTCTGTAATCTGA-39 (reverse) for RRM2,
and 59-AAGGACTCATGACCACAGTCCAT-39 (forward) and 59-CCAT-
CACGCCACAGTTTTC-39 (reverse) for glyceraldehyde-3-phosphate
dehydrogenase.
ChIP Assay. The ChIP assay was performed using the ChIP assay
kit following the manufacturer’s instructions. In brief, chromatin DNA
was cross-linked by formaldehyde and sheared by sonication in 200 ml of
SDS lysis buffer. After centrifugation and dilution, the cross-linked
protein-DNA complexes were precipitated by overnight incubation with
the primary antibodies against histone H3, Uhrf1, DNMT1, or without
any antibody as a negative control. The precipitated DNA was analyzed
by PCR using primers 59-CTGAACAGGCCGAACGGTATGAAGAC-39
and 59-GAATCGATGATGCGCTTCTTGTCAC-39 (for CpG island
sequences of 14-3-3s) and 59-GCTCTTGGCTAGGTAACTGGACTCTTG
-39 and 59- AGGGGCTTTCCTCATTCTGCCTGCTAC -3 (for non-CpG
island control sequences of 14-3-3s).
Genomic DNA Isolation, Bisulfite Modification, Methylation-
Specific PCR, and Sequencing. Genomic DNA was isolated
from MiaPaCa-2, G3K, and G3K/REV cells using the Qiagen Blood
and Cell Culture DNA Kit and modified by sodium bisulfite using
the CpGenome universal DNAmodification kit according to the supplier’s
protocol.
Methylation-specific PCR was performed as previously described
(Han et al., 2006). In brief, 10 mg of bisulfite-modified genomic DNAs
was subjected to PCR analysis using primers 59-TGGTAGTTTTTAT-
GAAAGGCGTC-39 and 59-CCTCTAACCGCCCACCACG-39 (for meth-
ylated sequence) or 59-ATGGTAGTTTTTATGAAAGGTGTT-39 and
59-CCCTCTAACCACCCACCACA-39 (for unmethylated sequence). The
PCR products were then subjected to separation and analysis by agarose
gel electrophoresis.
For sodium bisulfite sequencing, 10 mg of bisulfite-modified genomic
DNAswas first amplified using primers 59-GAGAGAGTTAGTTTGATT-
TAGAAG-39 and 59-CTTACTAATATCCATAACCTCC-39 and subcloned
into pGEM-T vectors (Promega, Madison, WI). Six independent clones
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for MiaPaCa-2 cells and four independent clones for G3K cells were
isolated and subjected to DNA sequencing.
Results
A Gemcitabine-Selected PDAC Cell Line Is Cross-
Resistant to Ara-C but Not to Other Anticancer Drugs.
To investigate acquired gemcitabine resistance, we subjected
the PDAC cell line MiaPaCa-2 to stepwise selection with
escalating concentrations of gemcitabine starting at 4 nM.
The final resistant cells were cloned and named G3K, and
were viable in the presence of 3000 nM gemcitabine. Authen-
tication using short tandem repeat sequence analysis showed
that G3K was derived from the parental MiaPaCa-2 cells (data
not shown). TheG3Kclonehas an estimated IC50 of 26.663.8mM,
whereas the parental MiaPaCa-2 cells have an IC50 of 4.1 6
1.3 nM to gemcitabine (Fig. 1, A and B). Thus, G3K cells are
∼6500-fold (RRF) more resistant to gemcitabine than the
parental MiaPaCa-2 cells.
We next examined if G3K cells are cross-resistant to the
gemcitabine analog, Ara-C, and other anticancer drugs using
MTT assay. As expected, G3K cells are∼3500-foldmore resistant
to Ara-C, with an IC50 of 388.4 6 48.9 mM, than the parental
MiaPaCa-2 cells, with an IC50 of 112.8 6 74.4 nM (Fig. 1B).
However, G3K cells did not show any significant resistance to
vinblastine, paclitaxel, or nocodazole, although G3K may
be slightly more resistant to 5-FU and mitoxantrone than
MiaPaCa-2 cells (Fig. 1C).
Ribonucleotide Reductase and 14-3-3s Are Upregu-
lated in G3K Cells. The finding that G3K cells are cross-
resistant to Ara-C and lack cross-resistance to multiple other
anticancer drugs prompted us to investigate if any known
mechanisms of gemcitabine resistance are upregulated in
G3K cells. These mechanisms include, but are not limited to,
overexpression of hENT1, RRM1, and RRM2 (Voutsadakis,
2011). We also examined 14-3-3s because it has been shown to
contribute to intrinsic resistance to gemcitabine (Li et al.,
2010). As shown in Fig. 2A, the protein level of hENT1 in G3K
cells remained the same as in MiaPaCa-2 cells, as determined
using Western blot analysis. However, the expression of
RRM1, RRM2, and 14-3-3s is drastically upregulated in G3K
cells compared with the parental MiaPaCa-2 cells. Interest-
ingly, the other members of the 14-3-3 protein family, 14-3-3u
and 14-3-3z, did not increase in expression in the G3K cells.
To further validate the increased expression of RRM and
14-3-3s, we next performed real-time RT-PCR analysis.
As shown in Fig. 2B, the mRNA levels of both RRM1 and
14-3-3s are significantly increased in G3K cells compared
with MiaPaCa-2 cells. We also found that the expression of
RRM1 and 14-3-3swas upregulated early during the selection
process by testing the cells with an intermediate level of
resistance generated during stepwise selections (Fig. 2C).
Although RRM1 remained in the same upregulated level in all
intermediate and the final G3K cells, 14-3-3s appears to be
further upregulated in G3K cells compared with the other
preceding intermediate cells. This observation suggests that
upregulation of both RRM1 and 14-3-3smay occur as an early
event of acquired gemcitabine resistance.
14-3-3s Overexpression Contributes to the Acquired
Gemcitabine Resistance. Because RRMs are well known
contributors to acquired gemcitabine resistance (Voutsadakis,
2011), we chose to further investigate the potential contribu-
tion of 14-3-3s to the acquired gemcitabine resistance in G3K
cells since its potential contribution to acquired gemcitabine
resistance has not yet been elucidated. For this purpose, we
knocked down 14-3-3s in G3K cells using siRNA and tested
if 14-3-3s knockdown compromises gemcitabine and Ara-C
resistance of G3K cells. As shown in Fig. 3A, 14-3-3s was
successfully knocked down in G3K cells by siRNA, and
the reduced 14-3-3s expression is accompanied by an ∼80%
reduction in gemcitabine resistance. Ara-C resistance was
also significantly reduced by 14-3-3s knockdown. Thus, 14-3-3s
overexpression in G3K cells may contribute to both gemcitabine
and Ara-C resistance.
To eliminate any potential issue with the use of the selected
final clone G3K in the above studies, we used the pool of the
Fig. 1. Drug-response profiles of MiaPaCa-2 and its derivative G3K cells. (A) Dose response of MiaPaCa-2 and G3K cells to gemcitabine treatment.
(B and C) IC50 of MiaPaCa-2 and G3K cells to gemcitabine, Ara-C, 5-FU, mitoxantrone, vinblastine, paclitaxel, and nocodazole (n = 4–8). ***P , 0.001;
**P , 0.01.
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intermediate resistant G500 cells (see Fig. 2C) and transiently
knocked down 14-3-3s expression using siRNA followed by
testing gemcitabine resistance. As shown in Fig. 3B, 14-3-3s
was successfully knocked down, and the reduced 14-3-3s
expression resulted in a 40% reduction in gemcitabine re-
sistance. We also tested the effect of 14-3-3s knockdown on
gemcitabine resistance using shRNA of sequences different
from that of siRNAs used in the above studies. As shown in Fig.
3C, 14-3-3s knockdown using shRNA also resulted in a signif-
icant reduction in gemcitabine resistance.
To further verify the role of 14-3-3s in acquired gemcitabine
resistance, we established a stable MiaPaCa-2 cell line with
overexpression of ectopic 14-3-3s. Figure 3D shows the stable
overexpression of ectopic 14-3-3s in MiaPaCa-2 cells and the
significantly increased resistance of the stable cells to both
gemcitabine and Ara-C, confirming that 14-3-3s overexpres-
sion causes gemcitabine and Ara-C resistance.
To validate the role of 14-3-3s in acquired gemcitabine
resistance of G3K cells, we created a partially revertant cell
line, G3K/REV, by continuously culturing G3K cells in the
absence of gemcitabine selection for 6 months and tested the
level of gemcitabine resistance and 14-3-3s expression. As
shown in Fig. 3E, G3K/REV cells have a significantly lower
IC50 to gemcitabine than the G3K cells (14.6 6 1.8 vs. 22.7 6
1.1 mM). The expression level of 14-3-3s in the G3K/REV cells
is also reduced compared with that of the G3K cells. Taken
together, we conclude that the upregulated 14-3-3s level
Fig. 2. Ribonucleotide reductase and 14-3-3s are upregulated in G3K cells.
(A) Western blot analysis of hENT1, RRM1 and 2, 14-3-3s, z, and u
expression in both MiaPaCa-2 and G3K cells. (B) Real-time RT-PCR
analysis of RRM1 and 14-3-3s mRNA in MiaPaCa-2 and G3K cells (n = 3;
P, 0.001). (C)Western blot analysis of RRM1 and 14-3-3s in the intermediate
gemcitabine-resistant cells G100, G500, and G1K. Actin was used as a
loading control for Western blot analyses, and glyceraldehyde-3-phosphate
dehydrogenase was used as an internal control for PCR analyses.
Fig. 3. 14-3-3s upregulation associates with and contrib-
utes to gemcitabine and Ara-C resistance. (A) 14-3-3s
knockdown reduces gemcitabine and Ara-C resistance in
G3K cells. G3K cells were transiently transfected with 14-3-
3s siRNA (Si) or scrambled control siRNA (Scr) followed by
Western blot analysis of 14-3-3s expression and MTT assay
of cellular response to gemcitabine and Ara-C. RRF =
IC50(Si or 14-3-3s)/IC50(Scr or Vec) (n = 3–4; ***P, 0.001). (B)
14-3-3s knockdown reduces gemcitabine resistance in
G500 cells. G500 cells were transiently transfected with
14-3-3s siRNA or scrambled control siRNA followed by
Western blot analysis of 14-3-3s expression and MTT
assay of cellular response to gemcitabine (n = 4; **P , 0.01).
(C) 14-3-3s stable knockdown reduces gemcitabine resistance
inG3K cells. G3K cells stably transfectedwith 14-3-3s shRNA
(Sh) or scrambled control (Scr) were established and subjected
to Western blot analysis and MTT assay of cellular response
to gemcitabine (n = 3; ***P , 0.001). (D) 14-3-3s over-
expression in MiaPaCa-2 cells causes gemcitabine and Ara-C
resistance. Stable MiaPaCa-2 cells with 14-3-3s overexpres-
sion (14-3-3s) or transfected with vector control (Vec) were
established and subjected to Western blot analysis and MTT
assay of cellular response to gemcitabine and Ara-C (n = 3–4;
***P , 0.001). (E) Association of 14-3-3s expression with
gemcitabine resistance. Expression of 14-3-3s and IC50 to
gemcitabine in MiaPaCa-2, G3K, and the revertant G3K/REV
cells was determined using Western blot analysis and MTT
assay, respectively (n = 4; **P , 0.01).
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likely contributes to the acquired gemcitabine resistance in
G3K cells, and that both the upregulated 14-3-3s expression
and gemcitabine resistance are partially reversible.
Differential Methylation of 14-3-3s Gene in MiaPaCa-2
and G3K Cells. The 14-3-3s gene was found frequently
hypermethylated and, thus, its expression was suppressed in
cancer cells (Ferguson et al., 2000). We hypothesize that the
14-3-3s gene in the parental MiaPaCa-2 cells may be hyper-
methylated, and that gemcitabine selection may have altered
the methylation status of the 14-3-3s gene, resulting in in-
creased transcription and expression of 14-3-3s. To test this
hypothesis, we first treated the parental MiaPaCa-2 cells
with a well known demethylating agent, 5-aza-2’-deoxycytidine
(5-Aza-dC, decitabine), that inhibits DNA methyltransferases,
and determined 14-3-3s expression level using Western blot.
As shown in Fig. 4A, 5-Aza-dC treatment increased 14-3-3s
expression in a dose-dependent manner. Thus, the 14-3-3s
gene is likely silenced in the parental MiaPaCa-2 cells by
methylation and perhaps reactivated in G3K cells.
Although it has been reported that gemcitabine does not
possess the pyrimidine ring modification at position 5, which is
responsible for inhibition of DNMTs and, thus, does not inhibit
DNA methylation (Goffin and Eisenhauer, 2002), a recent
study showed that gemcitabine reactivated several epigeneti-
cally silenced genes possibly by inhibiting DNMT1 (Gray et al.,
2012). Thus, it is possible that gemcitabine selection reacti-
vated 14-3-3s gene expression by inhibiting DNMT1. To test
this possibility, we treated the parental MiaPaCa-2 cells with
different concentrations of gemcitabine followed by Western
blot analysis of 14-3-3s expression. As shown in Fig. 4A, unlike
5-Aza-dC, gemcitabine treatment did not increase 14-3-3s
expression. Thus, reactivation of the 14-3-3s gene in G3K cells
is unlikely due to gemcitabine inhibition of DNMT1.
Next, we compared themethylation status of the 14-3-3s gene
in G3K and the parental MiaPaCa-2 cells using methylation-
specific PCR (MSP). As shown in Fig. 4B, the 14-3-3s gene in
the parental MiaPaCa-2 cells was amplified only by primers for
methylated sequences, whereas in G3K cells, it was amplified
only by primers for unmethylated sequences. Thus, the 14-3-3s
gene in the parental MiaPaCa-2 cells is methylated, whereas it
is demethylated in G3K cells. Analysis of the first exon with
27 CpG dinucleotides in the 14-3-3s gene that are known to be
methylated in cancer cells (Ferguson et al., 2000) using sodium
bisulfite sequencing shows that 25 of these CpG dinucleotides
in the parental MiaPaCa-2 cells are fully methylated, and the
remaining 2 are partially methylated (Fig. 4C). However, in
G3K cells, 23 of the 27 CpG dinucleotides are unmethylated,
and the remaining 4 are partially methylated. Clearly, the
methylations of the 14-3-3s gene in the parental MiaPaCa-2
cells have been removed in G3K cells.
Demethylation of the 14-3-3s Gene Is Reversible. As
shown earlier, the increased expression of 14-3-3s in G3K
cells is partially reversed in the partially revertant G3K/REV
cell line. The partial reversion in 14-3-3s expression may be
Fig. 4. Methylation status of the 14-3-3s gene in
MiaPaCa-2 and G3K cells. (A) Effect of 5-Aza-dC or
gemcitabine (Gem.) treatment on 14-3-3s expression.
MiaPaCa-2 cells were treated with increasing concen-
trations of 5-Aza-dC or gemcitabine followed byWestern
blot analysis of 14-3-3s and actin loading control. (B)
MSP analysis of MiaPaCa-2 and G3K cells. Con., control
MSP without genomic DNA input. (C) Sodium bisulfite
sequencing analysis of MiaPaCa-2 and G3K cells. The
27 CpG dinucleotides in the first exon of the 14-3-3s
gene are shown with solid circles for fully methylated,
open circles for unmethylated, and half-filled circles for
partially methylated CpG dinucleotides. The sequence
profile containing CpG dinucleotides 10–14 is shown for
both MiaPaCa-2 and G3K cells. The numbers in the
parentheses indicate the position of the first and last Cs
in this CpG island downstream of AUG start codon. (D)
Methylation status of the 14-3-3s gene in the revertant
G3K/REV cells. MSP was used to determine the methyl-
ation status of the 14-3-3s gene in G3K/REV cells with
MiaPaCa-2 and G3K cells as controls. M, primers for
methylated; U, primers for unmethylated.
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due to partial reversal of themethylation status of the 14-3-3s
gene. To test this possibility, we performed MSP of isolated
genomic DNAs from G3K/REV cells as described earlier.
Figure 4D shows that the 14-3-3s gene can be amplified by
primers for both methylated and unmethylated sequences,
indicating that the 14-3-3s gene in G3K/REV cells is likely
partially reversed, and that some cells have regained the
methylation of their 14-3-3s gene while others retain the
demethylated 14-3-3s gene. Thus, methylation and demethy-
lation of the 14-3-3s gene is likely partially reversible. The
incomplete reversal of 14-3-3s gene methylation following
removal of gemcitabine suggests that the increased 14-3-3s
expression in G3K cells is unlikely due to gemcitabine-
induced demethylation by inhibiting DNMT1, consistent with
the observation shown in Fig. 4A.
Previously, upregulation of 14-3-3s expression was also
observed in an Adriamycin-selected breast cancer cell line,
MCF7/AdVp3000, and it was decreased in the revertantMCF7/
AdVp3000/Rev cells (Liu et al., 2006) (see also Supplemental
Fig. 1A). However, the mechanism of 14-3-3s regulation in
these cell lines is not yet known. To determine if gene
methylation is involved in regulating 14-3-3s expression in
these cells, we performed MSP of isolated genomic DNAs from
the parental MCF7, Adriamycin-selected MCF7/AdVp3000,
and the revertant MCF7/AdVp3000/Rev cells with MiaPaCa-2
cells as a positive control. As shown in Supplemental Fig. 1B,
whereas the 14-3-3s gene in MiaPaCa-2 cells can be amplified
only using primers for methylated sequences, in all breast
cancer cells it can be amplified only using primers for the
unmethylated sequences. Thus, upregulation of 14-3-3s ex-
pression in MCF7/AdVp3000 cells and its reversal in MCF7/
AdVp3000/Rev cells is unlikely due to changes in methylation
status of the 14-3-3s gene.
Uhrf1 and DNMT1 Play an Important Role in
Regulating 14-3-3s Expression. To determine what regu-
lates the reversible methylation of the 14-3-3s gene inMiaPaCa-2
and G3K cells, we first compared the expression level of enzymes
important for DNAmethylation between the parental MiaPaCa-2,
gemcitabine-resistant G3K, and the partially revertant G3K/REV
cells usingWestern blot or real-timeRT-PCR. As shown in Fig. 5A,
whereas DNMT3a and DNMT3b were increased in G3K and
remained high in G3K/REV cells, DNMT1 is increased in G3K but
reduced back to the basal level in G3K/REV cells. The expression
pattern of these methyltransferases is peculiar and inconsistent
with the expression pattern of 14-3-3s in MiaPaCa-2, G3K, and
G3K/REV cells.
Another protein of importance in gene methylation, Uhrf1,
has been shown to play a major role in recruiting DNMTs
(Bostick et al., 2007; Sharif et al., 2007), and loss of Uhrf1
results in a 75% reduction in genomic methylation (Cokus et al.,
2008). Thus, we tested the expression pattern of Uhrf1. As
shown in Fig. 5A, Uhrf1 protein is reduced in G3K cells and
edged back up in the G3K/REV cells. The profile of Uhrf1
expression in these cells is consistent with the partially
reversible change in 14-3-3s expression and gene methylation
in these cells (see Discussion). Furthermore, because Uhrf1
has been shown to regulate p21 expression (Kim et al., 2009),
we next tested the expression of p21 in MiaPaCa-2, G3K, and
G3K/REV cells. As shown in Fig. 5A, the p21 protein level
shows an expression profile in these cells similar to that of 14-
3-3s, consistent with the possible regulatory role of Uhrf1 in
these cells.
To determine if the reduced Uhrf1 expression is possibly
responsible for increased expression of the 14-3-3s gene in
G3K cells, we knocked downUhrf1 in the parental MiaPaCa-2
cells using siRNA and tested its effect on 14-3-3s expression.
Figure 5B shows that 14-3-3s protein is dramatically in-
creased by Uhrf1 knockdown. This observation is confirmed
by real-time RT-PCR analysis of 14-3-3s mRNA (Fig. 5C).
To determine if DNMTs also contribute to 14-3-3s expression
regulation, we performed a similar experiment by knocking
down DNMT1, DNMT3a, and DNMT3b in MiaPaCa-2 cells.
Figure 5D shows successful knockdown of DNMT1, DNMT3a,
and DNMT3b as determined using Western blot or real-time
RT-PCR. However, only DNMT1 knockdown upregulated the
14-3-3s protein level. DNMT3a and DNMT3b knockdown did
not appear to affect 14-3-3s expression. The effect of DNMT1
knockdown on 14-3-3s expression was also confirmed by real-
time RT-PCR analysis (Fig. 5C). Taken together, we conclude
that both Uhrf1 and DNMT1 likely play important roles in
regulating 14-3-3s expression.
Uhrf1 Binds and Helps Recruit DNMT1 to CpG
Islands of 14-3-3s Gene. To further determine the role of
Uhrf1 and DNMT1 in regulating 14-3-3s expression and gene
methylation, we first determined if Uhrf1 binds to the CpG
islands in the first exon of the 14-3-3s gene inMiaPaCa-2 cells
using a ChIP assay. As shown in Fig. 6A, Uhrf1 was bound to
the CpG island but not to the CpG-free sequences in the
promoter region of the 14-3-3s gene in MiaPaCa-2 cells.
Knocking down Uhrf1 also reduced Uhrf1 binding to the CpG
islands of the 14-3-3s gene (Fig. 6B). Thus, Uhrf1 likely can
bind to the CpG island sequence of the 14-3-3s gene.
As shown in Fig. 5A, we found that DNMT1 expression was
increased in G3K cells, which is peculiar since methylation of
the 14-3-3s gene in G3K cells is reduced. However, because
Uhrf1 binding to CpG island sequences helps recruit DNMT1
to maintain the methylation status of the DNA, it is possible
that the reduced Uhrf1 expression in G3K cells reduces
DNMT1 recruitment despite the higher level of DNMT1 in
G3K cells. To test this possibility, we first compared the
binding of DNMT1 to the CpG island sequence of the 14-3-3s
gene between MiaPaCa-2 and G3K cells. As shown in Fig. 6C,
binding of DNMT1 to the CpG island sequence of the 14-3-3s
gene is indeed much less in G3K than in MiaPaCa-2 cells
despite the higher expression level of DNMT1 in G3K cells.
Uhrf1 knockdown in MiaPaCa-2 cells also reduced DNMT1
binding to the CpG island sequence of the 14-3-3s gene (Fig.
6D), indicating that DNMT1 could not be effectively recruited
to the CpG island sequence of the 14-3-3s gene in the absence
of Uhrf1. Thus, we conclude that Uhrf1 likely plays a major
role in regulating 14-3-3s expression by binding to its CpG
rich sequence, and helps recruit DNMT1 to the site to
reversibly methylate the 14-3-3s gene. The reduced Uhrf1
expression in G3K cells likely decreased DNMT1 recruitment
and methylation of the 14-3-3s gene, whereas the slight
increase in Uhrf1 level is responsible for partial reversal of
14-3-3s gene methylation in G3K/REV cells.
Gemcitabine Treatment Does Not Affect Uhrf1 and
DNMT1 Expression. To investigate if the altered ex-
pression of Uhrf1 and DNMT1 in G3K cells is potentially
due to gemcitabine treatments during selection, we per-
formed a Western blot analysis of these two proteins in
MiaPaCa-2 cells following treatments with gemcitabine at
different concentrations. As shown in Supplemental Fig. 2,
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gemcitabine treatments had no effect on Uhrf1 and DNMT1
expression. Thus, the mechanism of regulation of Uhrf1 and
DNMT1 expression in the drug-resistant cells remains to be
determined.
Discussion
Stepwise selections with anticancer drugs have been used
as a standard method to create model cell lines for laboratory
studies and identification of novel mechanisms of acquired
resistance. G3K cells selected with gemcitabine in this study
are clonal and cross-resistant to Ara-C. Considering the
similarity in structure, mechanism of action, and metabolism
between gemcitabine and Ara-C, we are not surprised to find
the cross-resistance of G3K cells to Ara-C. The observation of
increased expression of RRM is also as expected, as these
proteins have previously been shown to be upregulated and
contribute to acquired gemcitabine resistance in other
gemcitabine-selected cells (Goan et al., 1999; Davidson et al.,
2004). However, the findings of the upregulated expres-
sion of 14-3-3s via reversible epigenetic regulation during
gemcitabine selection and its role in acquired gemcitabine
resistance and cross-resistance to Ara-C are unexpected and
absolutely novel. These findings will shed light not only on
possible targeting of 14-3-3s for sensitization of acquired
gemcitabine resistance but also on further understanding of
the molecular mechanisms in epigenetic regulation of 14-3-3s
expression.
Fig. 5. Effect of Uhrf1 and DNMT1 on 14-3-3s expression. (A) Western blot analysis of Uhrf1, DNMT1, DNMT3a, and p21 expression as well as real-
time RT-PCR analysis of DNMT3b expression in MiaPaCa-2, G3K, and G3K/REV cells. (B–D) Effect of Uhrf1, DNMT1, DNMT3a, and DNMT3b
knockdown on 14-3-3s expression. MiaPaCa-2 cells were transiently transfected with scrambled control siRNA (Scr) or siRNAs (Si) targeting Uhrf1 (B),
DNMT1, DNMT3a, and DNMT3b (D) followed by Western blot analysis of Uhrf1, DNMT3a, and 14-3-3s or real-time RT-PCR analysis of DNMT3b and
14-3-3s (B–D) (n = 4–5; *P , 0.05; **P , 0.01; ***P , 0.001). Actin and glyceraldehyde-3-phosphate dehydrogenase were used as a loading control for
Western blot and internal control for PCR analyses, respectively.
Fig. 6. Binding of Uhrf1 and DNMT1 to the CpG island of
the 14-3-3s gene. (A) ChIP analysis of Uhrf1 binding to the
CpG island sequence or non-CpG island sequence of the
14-3-3s gene. (B andD) Effect of Uhrf1 knockdown onUhrf1
and DNMT1 binding to the CpG island sequence of the 14-3-3s
gene in MiaPaCa-2 cells. MiaPaCa-2 cells were transiently
transfected with scrambled control (Scr) or Uhrf1 siRNAs
(Si) followed by ChIP analysis of Uhrf1 and DNMT1 binding.
(C) DNMT1 binding to the CpG island of the 14-3-3s gene in
G3K cells is less than that in MiaPaCa-2 cells. ChIPs with
histone H3 antibody or without any primary antibody were
used as positive and negative controls, respectively. Normal
IgG was also used as a negative control, which did not
immunoprecipitate any DNA (data not shown). Ab, antibody.
Regulation of 14-3-3s Expression in Gemcitabine Resistance 567
 at A
SPET Journals on D
ecem
ber 24, 2016
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
14-3-3s, a homodimeric protein that functions as a chap-
erone, binds to .100 phosphoserine/phosphothreonine pro-
teins and plays important roles in cell survival (Li et al.,
2009). Upregulated expression of 14-3-3s has been found in
PDAC and appears to be associated with poor prognosis of
PDAC by causing resistance to gemcitabine (Hustinx et al.,
2005; Li et al., 2010). The possible role of 14-3-3s in re-
sistance to other anticancer drugs such as doxorubicin and
cisplatin has also been reported previously (Han et al., 2006,
2009; Liu et al., 2006; Neupane and Korc, 2008). Similar to
the finding of this study that 14-3-3s can be selected and
responsible for acquired gemcitabine resistance, it can also
be selected and responsible for acquired doxorubicin re-
sistance (Liu et al., 2006). However, in this study, we showed
that the increased 14-3-3s expression for drug resistance in
different cell lines is regulated by different mechanisms,
which have not been reported in any previous studies. The
finding of epigenetic regulation due to methylation changes
in the 14-3-3s gene during gemcitabine selection is novel,
and it likely occurs only in the parental cells such as
MiaPaCa-2 cells, where the 14-3-3s gene is epigenetically
silenced. It is, however, noteworthy that the methylation
change of the 14-3-3s gene observed here is in the clonal G3K
cells. A different G3K clone may not present a reduction in
14-3-3s gene methylation. It is also not clear if gemcitabine
selection of a different cancer cell line with methylation
suppression of the 14-3-3s gene can result in demethylation
of the gene. Future studies are warranted to test if gemcitabine
selection results in demethylation of the 14-3-3s gene in different
cancer cells.
Although some of the other members of the 14-3-3 protein
family, such as 14-3-3z and 14-3-3u/t, have been reported to
also contribute to (Maxwell et al., 2009; Neal et al., 2009) and
associate with (Hodgkinson et al., 2012) drug resistance, we
did not find upregulation in expression of 14-3-3z and 14-3-
3u/t in the gemcitabine-resistant G3K cells. This observation
suggests that 14-3-3z and 14-3-3u/t may not participate in
the acquired gemcitabine resistance in PDAC.
Although the detailed mechanism of 14-3-3s–mediated
drug resistance is unknown, the fact that it binds to various
proteins important for different cellular processes suggests
that it may work by binding to these proteins. Somatic
knockout of 14-3-3s in colon cancer cells has been shown to
cause drug-induced mitotic catastrophe by reducing cellu-
lar ability to arrest in the G2/M phase (Chan et al., 1999),
and increased 14-3-3s expression in breast cancer cells
makes cancer cells more resistant to drug-induced apopto-
sis (Liu et al., 2006), possibly due to 14-3-3s binding and
arresting cyclin B1 and CDC2 (Chan et al., 1999; Han et al.,
2006) and proapoptosis proteins such as Bax and Bad
(Samuel et al., 2001; Subramanian et al., 2001) in cytoplasm.
Nevertheless, it remains to be determined if 14-3-3s–mediated
gemcitabine resistance also occurs via mitotic catastrophe
and apoptosis.
The finding that reversible methylation of the 14-3-3s
gene is regulated by Uhrf1 and DNMT1 is novel and has not
been reported, although regulation of 14-3-3s expression by
methylation has been observed in cell line models and
clinical samples (Ferguson et al., 2000; Suzuki et al., 2000).
The finding that 14-3-3s expression is progressively upregu-
lated during gemcitabine selection is very intriguing, and
suggests that the gene demethylation may be progressive.
We are also the first to report that Uhrf1 and DNMT1
expression changes following stepwise gemcitabine selection,
which leads to failure of DNMT1 recruitment to the 14-3-3s
gene and subsequent demethylation and increased 14-3-3s
expression (Fig. 7). Although the decreased methylation of
the 14-3-3s gene in the drug-resistant G3K cells is in-
consistent with the increased expression of DNMT1, the
reduced level of Uhrf1 may be responsible for the decreased
methylation.
Uhrf1, a multidomain protein associated with cellular pro-
liferation and epigenetic regulation, binds to histones and
methyl-CpG dinucleotides with a preference for hemimethy-
lated CpG sites. The consequence of Uhrf1 binding was re-
cruitment of DNMT1 and histone deacetylase 1, resulting in
methylation of nascent DNA strands (Bostick et al., 2007; Sharif
et al., 2007). Thus, reduced Uhrf1 expression in G3K cells is
likely responsible for reduced methylation of the 14-3-3s gene
by reducing recruitment of DNMT1 protein to the CpG islands,
despite the presence of a high level of DNMT1. In MiaPaCa-2
cells, however, the high level of Uhrf1 may efficiently recruit all
DNMT1 despite low DNMT1 level for efficient methylation of
14-3-3s gene. Knocking down either Uhrf1 or DNMT1 in
MiaPaCa-2 cells would effectively reduce the level of the
recruiter (Uhrf1) or the pool of DNMT1 to be recruited for
methylation of the 14-3-3s gene, and consequently increase
14-3-3s expression. Furthermore, the slight increase of Uhrf1
Fig. 7. Schematic diagram of regulation of the 14-3-3s gene by reversible
methylation during gemcitabine selection. InMiaPaCa-2 cells, a high level
of Uhrf1 binds to and helps recruit DNMT1 to the methylated region of the
14-3-3s gene to maintain methylation. In G3K cells, Uhrf1 expression is
reduced and serves as a limiting factor. Thus, little DNMT1 is recruited to
the 14-3-3s gene to maintain methylation despite the presence of a high
level of DNMT1. In G3K/REV cells, the increase in Uhrf1 level helps
recruit more DNMT1 protein to the 14-3-3s gene, resulting in more
methylation and partial loss of 14-3-3s expression.
568 Qin et al.
 at A
SPET Journals on D
ecem
ber 24, 2016
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
expression in the G3K/REV cells may be responsible for the
reduced expression and increased methylation of the 14-3-3s
gene.
The findings on altered expression of Uhrf1 and DNMT1 in
G3K and G3K/REV cells also suggest that other genes that are
under epigenetic regulation, specifically DNA methylation,
may also change in their expression, similar to 14-3-3s. Indeed,
we found that p21, a known Uhrf1 downstream target gene,
has an expression profile similar to that of 14-3-3s in the
parental MiaPaCa-2, gemcitabine-resistant G3K, and rever-
tant G3K/REV cells. What other genes have similar expression
profiles in these cells and whether these genes, such as p21,
also contribute to the acquired gemcitabine resistance remain
to be investigated. It would also be of interest to determine if
use of DNMT inhibitors affects gemcitabine resistance of
MiaPaCa-2 cells in xenograft animal models, which may provide
guidance on future treatment options for combination therapy.
We are currently working toward this direction.
In summary, we identified 14-3-3s as an important contrib-
utor for acquired gemcitabine resistance and for Ara-C cross-
resistance in PDAC cells using a stepwise-selected and
gemcitabine-resistant cell line, and showed that upregulated
14-3-3s expression by gemcitabine selection was due to par-
tially reversible demethylation of its gene by reduced Uhrf1
expression in the gemcitabine-resistant derivative cells. Reversible
epigenetic regulation may play an important role in gemcitabine
response in pancreatic cancer treatment, and targeting epigenetic
regulation may provide a new direction for chemosensitization of
gemcitabine-resistant human pancreatic cancers.
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Supplemental Figure S1. 14-3-3σ up-regulation in Adriamycin-selected MCF7/AdVp3000 
cells is not due to gene demethylation. (A). Western blot analysis of 14-3-3σ expression in 
MCF7, MCF7/Advp3000 (AdVp), and MCF7/AdVp/Rev (Rev) cells. Actin was used as a 
loading control. (B). MSP analysis of 14-3-3σ gene in MCF7, MCF7/Advp3000 (AdVp), and 
MCF7/AdVp/Rev (Rev) cells with MiaPaC-2 cells as a control. U, primers for unmethylated; M, 
primers for methylated. Contl., control MSP without genomic DNA input. 
  
Supplemental Figure S2 
 
 
 
 
 
 
 
Supplemental Figure S2. Effect of gemcitabine treatment on Uhrf1 and DNMT1 expression. 
MiaPaCa-2 cells were treated with increasing concentrations of gemcitabine followed by 
Western blot analysis of Uhrf1, DNMT1, and actin loading control. 
 
